|
ATCC
non small cell lung cancer cell line a549 Non Small Cell Lung Cancer Cell Line A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A549/10__1074_slash_jbc__ra120__012893-420-0-7 Average 99 stars, based on 1 article reviews
non small cell lung cancer cell line a549 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
CLS Cell Lines Service GmbH
human non small cell lung carcinoma a549 cells ![]() Human Non Small Cell Lung Carcinoma A549 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A549+Cells/pmc11223245-34-0-9 Average 95 stars, based on 1 article reviews
human non small cell lung carcinoma a549 cells - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
ATCC
lps treatment eml4 alk fusion a549 isogenic cell line human ![]() Lps Treatment Eml4 Alk Fusion A549 Isogenic Cell Line Human, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/EML4-ALK+Fusion-A549+Isogenic+Cell+Line+Human/ppr0206806-29-5-13 Average 99 stars, based on 1 article reviews
lps treatment eml4 alk fusion a549 isogenic cell line human - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
a549 vim rfp ![]() A549 Vim Rfp, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A-549+VIM+RFP/bio_rxiv__2020__01__27__920371-150-0-1 Average 99 stars, based on 1 article reviews
a549 vim rfp - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
human lung carcinoma cell line a549 ![]() Human Lung Carcinoma Cell Line A549, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A549/pm33605950-61-20-26 Average 99 stars, based on 1 article reviews
human lung carcinoma cell line a549 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
DSMZ
a549 ![]() A549, supplied by DSMZ, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A-549/bio_rxiv__64898__2026__02__25__707964-197-9-31 Average 96 stars, based on 1 article reviews
a549 - by Bioz Stars,
2026-11
96/100 stars
|
Buy from Supplier |
|
ATCC
atcc ccl 185ig cell line ![]() Atcc Ccl 185ig Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/EML4-ALK+Fusion-A549%3B+CRISPR%2FCas9+Modified+Cell+line%3B+Human+(Homo+sapiens)%2C+Isogenic/10__1039_slash_D2LC00443G-158-8-8 Average 92 stars, based on 1 article reviews
atcc ccl 185ig cell line - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
ATCC
human adenocarcinoma ![]() Human Adenocarcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A-549%3B+Lung+Carcinoma%3B+Human/pm23100370-94-11-13 Average 99 stars, based on 1 article reviews
human adenocarcinoma - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
ATCC
human lung carcinoma ![]() Human Lung Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A-549%3B+Lung+Carcinoma%3B+Human/pm26014915-39-6-12 Average 97 stars, based on 1 article reviews
human lung carcinoma - by Bioz Stars,
2026-11
97/100 stars
|
Buy from Supplier |
|
InvivoGen
a549 dual rig i ko ![]() A549 Dual Rig I Ko, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A549-Dual+KO-RIG-I+Cells/pmc10877685-48-0-4 Average 95 stars, based on 1 article reviews
a549 dual rig i ko - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
InvivoGen
a549 ![]() A549, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A549-Dual+Cells/pmc12338309-130-0-5 Average 99 stars, based on 1 article reviews
a549 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
InvivoGen
a549 hace2 cells ![]() A549 Hace2 Cells, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/a549/A549-hACE2-TMPRSS2+Cells/pmc12902868-144-7-9 Average 99 stars, based on 1 article reviews
a549 hace2 cells - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
Image Search Results
Journal: ACS Omega
Article Title: The Role and Efficacy of JNK Inhibition in Inducing Lung Cancer Cell Death Depend on the Concentration of Cisplatin
doi: 10.1021/acsomega.4c01950
Figure Lengend Snippet: Effect of JNK inhibition on A549 cell viability as a function of cisplatin concentration. (a, b) 7.5 μg/mL concentration of cisplatin becomes lethal in combination with JNK inhibitor SP600125. However, at higher cisplatin concentrations, the inhibitor either protects against cisplatin-induced cell death (a) or does not have any effect (b). (c) Similar effects are observed in the colon cancer cell line DLD-1. (d–g) SP600125 potentiates the appearance of cells with apoptotic morphology in 7.5 μg/mL cisplatin-treated A549 cells (d, e), in contrast to 30 μg/mL cisplatin-treated A549 cells (f, g). Relative cell viability is cell viability after 72 h treatment normalized by initial viability (measured by the MTT method). Representative test results (all measurements were performed in quadruplicate) from more than five experiments are presented. Fluorescent pictures were obtained with a mixture of AO/EB dyes as described in the section. SP—JNK inhibitor SP600125 (20 μM).
Article Snippet:
Techniques: Inhibition, Concentration Assay
Journal: ACS Omega
Article Title: The Role and Efficacy of JNK Inhibition in Inducing Lung Cancer Cell Death Depend on the Concentration of Cisplatin
doi: 10.1021/acsomega.4c01950
Figure Lengend Snippet: JNK inhibitor SP600125 reduces JNK target transcription factor c-Jun phosphorylation in cisplatin-treated A549 cells. Different concentrations of cisplatin were used. (a) Representative Western blots from 20 and 40 h of treatments are shown. Total protein Coomassie-stained polyacrylamide gels serve as loading controls. (b) Repeated addition (after 24 h) of SP potentiates suppression of c-Jun phosphorylation in response to cisplatin treatment. (c) Repeated addition of SP strengthens the protective effect of JNK inhibition at 15−30 μg/mL concentrations of cisplatin in A549 cells. SP—JNK inhibitor SP600125 (20 μM). p *** < 0.0005, N = 3.
Article Snippet:
Techniques: Phospho-proteomics, Western Blot, Staining, Inhibition
Journal: ACS Omega
Article Title: The Role and Efficacy of JNK Inhibition in Inducing Lung Cancer Cell Death Depend on the Concentration of Cisplatin
doi: 10.1021/acsomega.4c01950
Figure Lengend Snippet: Cisplatin concentration-dependent effect of different JNK inhibitors on A549 cell viability. Different JNK inhibitors show the same dependence on cisplatin concentration on cell viability. Statistically significant reduction in cell viability is observed at 7.5 μg/mL cisplatin in combination with 10 μM AS601245 (a), 10 μM bentamapimod (b), 2 μM JNK inhibitor IX (c), and 5 μM XG-102 (d). Representative test results (all measurements were performed in quadruplicate) from more than five experiments are presented. (e) Reduction in c-Jun phosphorylation upon the addition of JNK inhibitor XG-102, as determined by Western blot. Representative Western blots are shown. Total protein Coomassie-stained polyacrylamide gels serve as loading controls.
Article Snippet:
Techniques: Concentration Assay, Phospho-proteomics, Western Blot, Staining
Journal: ACS Omega
Article Title: The Role and Efficacy of JNK Inhibition in Inducing Lung Cancer Cell Death Depend on the Concentration of Cisplatin
doi: 10.1021/acsomega.4c01950
Figure Lengend Snippet: Activation of TP53 in A549 cells in response to different concentrations of cisplatin. (a, b) Expression and phosphorylation at serine-6 is induced by cisplatin and is maximal at 15 μg/mL (6 h of cisplatin treatment). (c, d) Prolonged and increasing expression and phosphorylation of TP53 in cells treated with either 7.5 μg/mL or 30 μg/mL of cisplatin. (e) TP53 activator nutlin-3a potentiates cisplatin-induced decrease in cell viability. (f) Nutlin-3a reduces viability of cisplatin + SP600125-treated cells. C—control without cisplatin; Nut—nutlin-3a (10 μM); SP—SP600125 (20 μM). Representative test results (all measurements were performed in quadruplicate) from more than five experiments are presented, p ** < 0.005, p *** < 0.0005, N = 4. (g) Nutlin induces expression of TP53. Representative Western blots are shown. Total protein Coomassie-stained polyacrylamide gels serve as loading controls.
Article Snippet:
Techniques: Activation Assay, Expressing, Phospho-proteomics, Control, Western Blot, Staining
Journal: ACS Omega
Article Title: The Role and Efficacy of JNK Inhibition in Inducing Lung Cancer Cell Death Depend on the Concentration of Cisplatin
doi: 10.1021/acsomega.4c01950
Figure Lengend Snippet: Involvement of AKT signaling pathway in cisplatin-induced A549 cell death. (a) AKT protein level does not depend on cisplatin concentration. 6-h-long exposure is presented in the Western blot picture. (b) Phosphorylation/activation of AKT is cisplatin concentration-dependent. 6-h-long exposure is presented in the Western blot picture. (c) AKT protein level does not change during 40 h of cisplatin treatment. (d) Dynamics of AKT activation following cisplatin (7.5 or 30 μg/mL) treatment. (e, f) AKT inhibitor capivasertib enhances cell death at all concentrations of cisplatin used both in the absence (e) and presence (f) of JNK inhibitor SP600125. (g, h) GSK3-β inhibitor SB415286 protects A549 cells from cisplatin both in the absence (g) and presence (h) of JNK inhibition. Representative test results (all measurements were performed in quadruplicate) from more than five experiments are presented. p*<0.05, p**<0.005, p***<0.0005, N = 4. (i) Capivasertib inhibits AKT activity as shown by the inhibition of AKT molecular target GSK3-β phosphorylation at serine-9. Representative Western blots are shown. Total protein Coomassie-stained polyacrylamide gels serve as loading controls. C—control without cisplatin; CAP—capivasertib (10 μM); SP—SP600125 (20 μM), SB—GSK3 inhibitor SB415286 (15 μM).
Article Snippet:
Techniques: Concentration Assay, Western Blot, Phospho-proteomics, Activation Assay, Inhibition, Activity Assay, Staining, Control
Journal: ACS Omega
Article Title: The Role and Efficacy of JNK Inhibition in Inducing Lung Cancer Cell Death Depend on the Concentration of Cisplatin
doi: 10.1021/acsomega.4c01950
Figure Lengend Snippet: Opposite changes in TP53 and AKT phosphorylation following SP600125 treatment of A549 cells exposed to different concentrations of cisplatin. (a) Expression of TP53 is increased in response to the combination of SP + 7.5 μg/mL cisplatin, in contrast to the combination of SP + 30 μg/mL cisplatin. (b) Phosphorylation of TP53 (serine-6) is increased in response to the combination of SP + 7.5 μg/mL cisplatin, in contrast to the combination of SP + 30 μg/mL cisplatin. (c) Phosphorylation of AKT (threonine-308) is decreased in response to the combination of SP + 7.5 μg/mL cisplatin, in contrast to the combination of SP + 30 μg/mL cisplatin. Representative Western blots are shown. Total protein Coomassie-stained polyacrylamide gels serve as a loading control. SP—JNK inhibitor SP600125 (20 μM); 20 h of treatment.
Article Snippet:
Techniques: Phospho-proteomics, Expressing, Western Blot, Staining, Control
Journal: Analytical methods : advancing methods and applications
Article Title: Nonspecific nuclear uptake of anti-MUC1 aptamers by dead cells: the role of cell viability monitoring in aptamer targeting of membrane-bound protein cancer biomarkers.
doi: 10.1039/d0ay01878c
Figure Lengend Snippet: Fig. 1 Aptamer and RND1 control binding to the MUC1 peptide and cell line lysates. (A) The ELONA response obtained for 5TR1, 5TR4, 5TRG2, S22 aptamer and RND1 control binding to MUC1 peptide (MUC1) and milk powder control (MP) layers. Significant binding by the biotin-labelled aptamers to wells containing the MUC1 peptide in comparison to the milk powder control layer only is denoted with an asterisk (*, p < 0.05). Error bars represent the standard deviation of the mean (n ¼ 4). Two-way ANOVA tests were performed using the Tukey–Kramer post hoc test, with results from the two-way ANOVA annotated in the graph. (B) SDS-PAGE and corresponding south- western blots of MCF-7, Hs578T, A549, SW480, and SW620 cell lysates using biotin-labelled 5TR1 aptamer, RND1 and no aptamer controls. Southwestern blots of cancer cell line lysates by the 5TR4, 5TRG2, and S22 aptamers shown in ESI as Fig. S1A–C.†
Article Snippet: Cell lines and tissue culture Adherent human breast carcinoma cell lines: MCF-7 (ATCC: HTB-22) and Hs578T (ATCC: HTB-126), and the
Techniques: Control, Binding Assay, Comparison, Standard Deviation, SDS Page, Western Blot
Journal: iScience
Article Title: Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells
doi: 10.1016/j.isci.2024.109068
Figure Lengend Snippet:
Article Snippet: A549-Dual RIG-I KO ,
Techniques: Isolation, Recombinant, WST-1 Assay, Screening, Control, Software
Journal: Molecular Pharmaceutics
Article Title: Fabrication of RIG-I-Activating Nanoparticles for Intratumoral Immunotherapy via Flash Nanoprecipitation
doi: 10.1021/acs.molpharmaceut.5c00125
Figure Lengend Snippet: RANs are endosomolytic, immunostimulatory in vitro, and stable in serum. (A) Experimental schematic of Gal8-YFP assay used to measure endosomolytic activity of RANs and representative microscopy images of MDA-MB-231 Gal8-YFP cells treated with a RAN formulation and a PBS control. (B) Dose response curves of MDA-MB-231 Gal8-YFP cells treated with indicated RAN formulations ( n = 3 biological replicates per group). All RANs promoted endosomolytic activity in a dose-dependent manner as indicated by (C) calculated EC 50 values of each RAN formulation. P values determined by an ordinary one-way ANOVA test with Tukey’s test for multiple comparisons. (D) Dose response curves for relative IFN-I production by A549-Dual reporter cells treated with RAN formulations, micelleplex, and free SLR14 controls ( n = 3 biological replicates per group). (E) Calculated EC 50 values for relative IFN-I production. P values determined by an ordinary one-way ANOVA test with Dunnett’s test for multiple comparisons. (F) Dose response curves for IFN-β secretion by isolated bone marrow-derived macrophages (BMDMs) treated with RAN formulations ( n = 2 biological replicates per group). (G) Calculated EC 50 values and (H) maximum secreted IFN-β levels. P values determined by an ordinary one-way ANOVA test with Tukey’s test for multiple comparisons. (I) Serum stability analysis of RAN 2 kDa (green), RAN 10 kDa (yellow), and micelleplex (red) immunostimulatory activity in A549-Dual IFN-I reporter cells after 24 h incubation in either 50% FBS or PBS at 37 °C. Replicates are biological, and data are shown as mean ± SD * signifies P < 0.05, ** signifies P < 0.01, *** signifies P < 0.001, **** signifies P < 0.0001.
Article Snippet:
Techniques: In Vitro, Activity Assay, Microscopy, Formulation, Control, Isolation, Derivative Assay, Stability, Analysis, Incubation
Journal: ACS Omega
Article Title: Enzymatic Glucosylation Enhances the Solubility of Niclosamide but Abrogates Its Therapeutic Efficacy
doi: 10.1021/acsomega.5c12185
Figure Lengend Snippet: Antiviral and cytotoxicity properties of Nic and Nic-Glc against SARS-CoV-2 in (A) Vero E6 cells, (B) A549-hACE2 cells, and (C) Huh7.5 cells. Percent viral infectivity is shown on left y -axis and percent cell viability is shown on the right y -axis (mean ± SD; n = 4). All values are normalized to the nontreated controls. We also confirmed that Remdesivir showed activity as expected and that DMSO alone had no significant antiviral activity ( Figures S3 and S4 , Table S1 ).
Article Snippet: For SARS-CoV-2 experiments in Vero E6 and
Techniques: Infection, Activity Assay